A dodecapeptide corresponding to the external N-terminal sequence of the human low-density-lipoprotein (LDL) receptor was synthesized. Antibodies raised in rabbits against the peptide were purified and were shown to react specifically with the peptide and with human LDL receptor of fibroblasts, HeLa cells and lymphocytes using binding studies and immunoblotting. By indirect immunogold analysis, antibodies bound to the LDL receptor of human lymphocytes could be revealed as clusters. Anti-receptor peptide immunoglobulins specifically bound to the human HeLa cell's LDL receptor with a lower affinity than LDL (Kd x 3). The anti-receptor peptide immunoglobulins and l25l-labelled-LDL competed with each other for the LDL-receptor sites. Antibodies failed to react with lymphocytes of subjects with the homozygous form of familial hypercholesterolaemia. Cross-reactivity with the dodecapeptide of the bovine LDL receptor was limited, but this cross-reactivity was confirmed by the binding of anti-receptor peptide immunoglobulins to the LDL receptor from bovine lymphocytes.
INTRODUCTION
Studies on cultured human fibroblasts [1] , HeLa cells [2] and blood lymphocytes [3] have defined a receptormediated pathway by which cells bind, internalize and degrade low-density lipoproteins (LDLs). The human LDL-receptor sequence determined by Yamamoto et al. [4] revealed that the protein possesses at least five domains.
The N-terminal domain (292 amino acids) is located at the external surface of the plasma membrane and is generally considered as corresponding to the binding domain of the receptor [5] . Schneider et al. [6] have shown that antibodies raised against a synthetic peptide corresponding to the first 16 amino acid residues of the N-terminus of bovine LDL receptor recognized the bovine receptor. These antibodies also cross-reacted to a significant extent with the human LDL receptor, although the corresponding N-terminal sequences differ in several positions in the two species.
In the present study we have synthesized the N-terminal dodecapeptide corresponding to the human LDL-receptor sequence. Antibodies raised against this peptide were shown to react with the LDL receptor on human fibroblasts, HeLa cells and lymphocytes. They also partially inhibit 1251-LDL binding. Their cross-reactivity with bovine lymphocytes has been determined.
EXPERIMENTAL Lipoproteins
Human LDL [density (p) 1.030-1.055 kg/I] and HDL3 (p 1.12-1.21 kg/l) were isolated from fresh plasma of normal healthy donors by sequential ultracentrifugation [7] .
Lipoprotein-deficient serum (LPDS) (p > 1.25 kg/1) was prepared from a pool of fresh serum by subjecting this material to two centrifugation steps at 100000 g in a 50.2 Ti Rotor in a Beckman L.8 ultracentrifuge at 4°C for 24 h. LDL was radiolabelled with Na125I (Amersham) by the iodine monochloride method described by MacFarlane [8] . The specific radioactivity was expressed in c.p.m. and is indicated in the Figure legends. The radioactivity counting efficiency was 60 %.
Methylated LDL was prepared by the method of Weisgraber et al. [9] . An antibody against LDL was raised in rabbits, and immunoglobulins were prepared by Na2SO4 (170 g/l) precipitation. This antibody recognized both LDL and methylated LDL.
Synthesis of the N-terminus peptide of the LDL receptor
The N-termini peptides of the human [4] and bovine [6] LDL receptor (Table 1) were synthesized by solid-phase technology as described by Merrifield [10] . Immunoglobulins were radiolabelled with Na'251 by the chloramine-T technique [11] . The specific radioactivity ranged between 500 and 1000 c.p.m./ng of protein and is indicated in Figure legends .
Before rabbit immunization, preimmune serum was obtained from the same rabbits and immunoglobulins were precipitated by Na2SO4 to be used as control. In some cases (indicated in Figure legends) [14] of the method of Boyuim [15] . Blood lymphocytes were also isolated, using the same conditions, from cow. The cells were cultured for 72 h in RPMI-1640 medium supplemented with L-glutamine (2 mM), penicillin (100 units/ml), streptomycin (100 ,tg/ ml), BSA (10 g/l) and human HDL3 (300 ,ug/ml) to enhance the requirement for cholesterol and so stimulate LDL-receptor binding capacity [16] . After preincubation, the cells were harvested by centrifugation (350 g, 10 min, 4°C) and resuspended in 6 ml of ice-cold PCA working buffer before centrifugation and resuspension at a final concentration of 20 x 106 cells/ml. Monolayer binding studies Binding studies of "251-labelled LDL or "25I-labelled ARP-Ig, performed at 4 'C on nearly confluent cells as described by Goldstein et al. [17] for LDL gave a measure of membrane receptor binding of the lipoproteins. In order to assess the rates of internalization and degradation of the lipoproteins, assays were performed at 37 'C using the Goldstein & Brown procedure [1] . These assays were performed in triplicate. Non-specific binding was obtained by adding unlabelled LDL in excess (1 mg/ml) to the binding assay system or by the binding of 251I-labelled preimmune immunoglobulins. Indirect immunofluorescence analysis of the LDL receptor on lymphocytes Lymphocyte binding assays were carried out in 750 utl polyethylene Microfuge tubes that had been precoated with BSA (10 g/l). Incubations were conducted in an ice bath in a 4 'C cold-room to avoid interference due to endocytosis; 2 x 106 cells were used for each binding test in a final volume of 100 ,ul of PCA buffer.
LDL binding test. LDL in PCA buffer was added to lymphocytes at a final concentration of 25,ag/ml.
Incubation was performed for 45 min, after which each tube was centrifuged in the 12042 rotor of a Sigma 202 MK centrifuge (10000g, 2 min, 4 C). The supernatant was discarded and the cell pellet rinsed with 300 ,u of PCA buffer then with 300,tl of 10000 fetal serum as described by Ho et al. [14] . The cells were then incubated for 45 min with rabbit immunoglobulins specific for human LDL (50 Ig/ml final concn.). There-after the cells were washed twice with PCA buffer and centrifuged (4000 g, 5 min, 4°C). The last 45 min incubation was performed with fluorescein-labelled antirabbit immunoglobulins (FITC-IgG; Pasteur Diagnostic) diluted 1:20 (v/v) with PCA buffer. After incubation, the cells were washed twice with PBS and centrifuged (4000 g, 5 min, 4°C). The pellet was fixed by resuspension in 200 fll of paraformaldehyde (10 g/l) in PBS and immediately used for cytofluorimetric studies.
ARP-Ig binding test. Affinity-purified ARP-Ig was incubated at appropriate concentrations (usually 5 ,tg/ ml) for affinity-purified ARP-Ig) with cells for 45 min at 4°C, then all washing steps and further incubations with FITC-IgG were performed as described above for the LDL binding test.
Blanks were prepared in which cells were incubated with preimmune immunoglobulins or with PCA buffer at each step, and lastly with FITC-IgG. Fluorescence flow cytometry Stained lymphocyte suspensions were analysed for surface fluorescence in an Orthocytofluorograf 50 H (Orthodiagnostic System Westwood TIA) equipped with argon and helium-neon lasers focused at the same point.
Two optical parameters were used to determine the lymphocyte populations: the light scattered at narrow angles (argon laser at 488 nm) and the axial light ion (helium-neon laser). Fluorescence signals corresponding to the light-scattering characteristics of lymphocytes were recorded to produce a histogram of lymphocytes counted against fluorescence intensity. The results are expressed as the percentage of lymphocytes with a fluorescence intensity above the threshold (0% F).
Electrophoresis and ligand blotting
Cell extracts of fibroblasts and HeLa cells were prepared by using n-octyl f-D-glucopyranoside (40 mM) and partially purified on a DEAE-trisacryl column (IBF, Villeneuve la Garenne, France) as described by Beisiegel et al. [18] .
For dot-blot analysis [19] 
RESULTS
Antipeptide receptor specificity Immune sera and purified immunoglobulins from LDL-receptor-peptide-immunized animals were first tested by immunoenzymometry for their antipeptide reactivity. Both the human and the bovine peptides were coated on microtitre plates. As Fig. 1(a) shows, antibodies raised against the human peptide exhibited a high affinity for this antigen, but also cross-reacted to a significant extent with the bovine peptide. By contrast, non-specific binding of preimmune immunoglobulins was very low.
The specificity of human antipeptide immunoglobulins was then shown by a competitive immunoenzymometric assay. The human peptide was coated on the solid phase and both the human and bovine peptides were used as competitor (Fig. lb) 000) was also detected. This is probably a proteolytic product of the receptor that has been described by Schneider et al. [23] and that was retained on an IgG-C7 column [23] . A large excess of preimmune immunoglobulins (200 /tg/ml) failed to react with fibroblast and HeLa-cell extracts, and only 20 ,ug of affinity-purified ARP-Ig/ml are necessary to obtain a good reactivity. This confirmed the specificity of the ARP-Ig (Fig. 2) . Binding studies at 4 0C on fibroblasts and HeLa cells
Binding curves (Fig. 3) were constructed by incubation of '25I-labelled-ARP-Ig at 4°C with monolayers of HeLa (Fig. 3c) (Fig. 4) Binding of 10 4wg of 125I-LDL/ml was reduced by 500 with 200,g of affinity-purified ARP-Ig/ml. No competition was found with preimmune immunoglobulins, and a weak competition was found with HDL3 (Fig. Sa) . These HDL3 contained very small amounts of apolipoprotein E (< 1 %) as measured by immunoenzymometry, and this content could account for this weak competition.
Unlabelled LDL competed with "251-labelled ARP-Ig. Binding of 20,ug of '251-labelled ARP-Ig/ml was reduced by 500 with 3 ,ug of LDL/ml. Complete inhibition was achieved with 50 ug of LDL/ml; no competition was found with preimmune immunogobulins (Fig. Sb) and this was the case for preimmune immunoglobulins from six different rabbits, including rabbits used for peptide immunization. Neither LDL nor ARP-Ig competed with 1251I-labelled preimmune immunoglobulins for non-specific binding (results not shown).
Immunogold analysis of ARP-Ig binding on lymphocytes
Lymphocytes from venous blood of normal donors were incubated for 48 h in RPMI/BSA medium supplemented with HDL3 to deplete their cholesterol pools and produce maximal synthesis of LDL receptors [16] . Thereafter they were chilled to 4°C and incubated for 45 min with affinity-purified ARP-Ig or with LDL. After washing, surface-bound ARP-Ig was detected by incubation with gold-labelled anti-rabbit immunoglobulins, which were revealed by electron microscopy; surface-bound LDL were detected after further incubation with rabbit anti-LDL then with the same gold-labelled anti-rabbit immunoglobulins.
With preimmune rabbit immunoglobulins used as control, no gold particles could be detected at the lymphocyte surface (results not shown). At 4°C, some LDL and ARP-Ig became attached to the surface of the cells. The general pattern of distribution of the gold spheres seemed to be the same for LDL and ARP-Ig (Fig. 6) 
%).
Lymphocytes from the two FH homozygote subjects could not bind either LDL or ARP-Ig, and the number of fluorescent cells was not significantly different from the non-specific binding, T0.
Cross-reactivity of the ARP-Ig was tested with three different preparations of bovine lymphocytes: preimmune immunoglobulins failed to react with bovine lymphocytes (700 of fluorescence cells), but ARP-Ig bound to lymphocytes (150 of fluorescent cells). Quantitative cross-reactivity was difficult to evaluate, because LDL binding (20 0%) of fluorescent cells was also lower with bovine lymphocytes. DISCUSSION The use of antipeptide antibodies offers the possibility of focusing the immune response on a predetermined region of a protein. In this case, the N-terminal peptide of LDL receptor was chosen because it was a part of a domain known to be localized at the surface of the cells [6] and therefore accessible to the external environment. The peptide was coupled to carrier proteins using carbodi-imide activation of the carboxy groups. By using this linkage, the N-terminus of the peptide was thus exposed in a similar manner as in the native protein.
Results showed that immunization with this conjugated peptide resulted in the production of specific antibodies elicited mainly against the N-terminus of the LDL receptor.
The whole immunoglobulin fraction and specific immunoglobulins purified from it reacted with the peptide and with the partially purified human receptor as determined by immunoblotting techniques. When incubated with human fibroblasts, HeLa cells and lymphocytes, the antibody bound to the LDL receptor and could be revealed in clusters by indirect immunogold assay. The specificity of this reaction was confirmed by the failure of the antibody to bind to lymphocytes from two patients with the homozygous form of familial hypercholesterolaemia that lack LDL receptors. The affinity of 1251-labelled affinity-purified ARP-Ig for HeLa cells was determined. Its Most of the monoclonal and polyclonal antibodies described have been raised against LDL receptor from bovine adrenal gland [24] , and only one monoclonal antibody was raised against human LDL receptor [25] . Our anti-receptor antibody was also raised against the human LDL receptor. Schneider et al. [6] raised an antibody against the N-terminal bovine receptor peptide which bound to the LDL receptor of human fibroblasts and bovine adrenal cortex, but failed to compete with LDL for receptor binding. We think that the competition between our peptide antibody and LDL involves a proximity of the binding domains, but not necessarily identity. This hypothesis could explain the partial inhibition of the 1251-labelled-LDL binding by the ARP-Ig (Fig. 5a ), even at high concentrations (200 /,jg/ml). The different behaviour of the present antibodies and those of Schneider et al. [6] probably derives from differences in the sequences of the peptides used for immunization; the synthetic peptide used by Schneider et al. [6] is larger by four amino acids and the bovine and human N-terminal dodecapeptides differ significantly in their sequence by the nature of four residues. These differences can induce a change in the conformation between the two peptides and then between antibodies raised against peptides. The approach that we used, if applied to peptide sequences along the length of the molecule, might enable one to study structure-function relationships within the receptor itself. The antibody could be also used to quantify in human lymphocytes the LDL-receptor binding capacity [26] .
